{"title":"比美珠单抗用于治疗斑块型银屑病","authors":"S. Chaplin","doi":"10.1002/psb.2003","DOIUrl":null,"url":null,"abstract":"Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bimekizumab for the treatment of plaque psoriasis\",\"authors\":\"S. Chaplin\",\"doi\":\"10.1002/psb.2003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
